Drug Trial Radar · NCT01076764
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Last checked: Nov 19, 2026Latest source record: May 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13,220
Actual
Start
Apr 2010
Primary completion
May 2013
Study completion May 2013
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 26, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: * To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: * To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otamixaban as compared to UFH + Eptifibatide * To document the effect of Otamixaban on rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction as compared to UFH + eptifibatide * To document the effect on mortality (all cause death) of Otamixaban as compared to UFH + eptifibatide * To document the safety of Otamixaban as compared to UFH + eptifibatide * To document the effect of Otamixaban on thrombotic procedural complications during the index Percutaneous Coronary Intervention (PCI) as compared to UFH + eptifibatide
Conditions
- Acute Coronary Syndrome
Interventions
OtamixabanDrug
Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion
Placebo (for Otamixaban)Drug
Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion
UFHDrug
Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion
Placebo (for UFH)Drug
Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion
EptifibatideDrug
Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion
Placebo (for Eptifibatide)Drug
Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Adjudicated double composite of all-cause of death and new myocardial infarctionTime frame: from randomization (day 1) to day 7
- Safety: Adjudicated Thrombolysis In Myocardial Infarction (TIMI) significant bleeding (composite of TIMI major and minor)Time frame: from day 1 to day 7
Locations
607 sites in 55 countries. Site status is shown where the registry gives one.
Investigational Site Number 840015
Huntsville, Alabama
Investigational Site Number 840569
Phoenix, Arizona
Investigational Site Number 840703
Phoenix, Arizona
Investigational Site Number 840101
Anaheim, California
Investigational Site Number 840151
Anaheim, California
Investigational Site Number 840213
Beverly Hills, California
Investigational Site Number 840572
Huntington Beach, California
Investigational Site Number 840201
Long Beach, California
Investigational Site Number 840071
Los Angeles, California
Investigational Site Number 840557
Los Angeles, California
Investigational Site Number 840903
Northridge, California
Investigational Site Number 840065
San Francisco, California
Investigational Site Number 840561
Santa Rosa, California
Investigational Site Number 840721
Littleton, Colorado
Investigational Site Number 840551
Bridgeport, Connecticut
Investigational Site Number 840166
New Haven, Connecticut
Investigational Site Number 840520
Washington D.C., District of Columbia
Investigational Site Number 840185
Fort Lauderdale, Florida
Investigational Site Number 840028
Jacksonville, Florida
Investigational Site Number 840047
Lake Mary, Florida
Investigational Site Number 840500
Melbourne, Florida
Investigational Site Number 840706
Miami, Florida
Investigational Site Number 840009
Ocala, Florida
Investigational Site Number 840146
Ocala, Florida
Investigational Site Number 840577
Orlando, Florida
Investigational Site Number 840021
Sarasota, Florida
Investigational Site Number 840902
St. Petersburg, Florida
Investigational Site Number 840508
Tampa, Florida
Investigational Site Number 840719
Gainesville, Georgia
Investigational Site Number 840532
Boise, Idaho
Investigational Site Number 840105
Aurora, Illinois
Investigational Site Number 840190
Chicago, Illinois
Investigational Site Number 840205
Chicago, Illinois
Investigational Site Number 840521
Harvey, Illinois
Investigational Site Number 840148
Joliet, Illinois
Investigational Site Number 840042
Hammond, Indiana
Investigational Site Number 840554
Indianapolis, Indiana
Investigational Site Number 840560
Muncie, Indiana
Investigational Site Number 840904
Ames, Iowa
Investigational Site Number 840058
West Des Moines, Iowa
Showing 40 of 607 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.